Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 19 studies | 38% ± 13% | |
lung | 18 studies | 47% ± 16% | |
intestine | 11 studies | 39% ± 15% | |
kidney | 9 studies | 45% ± 9% | |
brain | 7 studies | 31% ± 10% | |
liver | 7 studies | 35% ± 19% | |
bone marrow | 6 studies | 26% ± 12% | |
pancreas | 5 studies | 57% ± 24% | |
eye | 5 studies | 33% ± 9% | |
uterus | 5 studies | 53% ± 20% | |
lymph node | 5 studies | 45% ± 10% | |
placenta | 4 studies | 51% ± 16% | |
prostate | 4 studies | 27% ± 7% | |
breast | 4 studies | 46% ± 6% | |
adrenal gland | 3 studies | 42% ± 8% | |
esophagus | 3 studies | 49% ± 28% | |
skin | 3 studies | 34% ± 5% | |
thymus | 3 studies | 50% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3923.09 | 1445 / 1445 | 100% | 332.04 | 183 / 183 |
lung | 100% | 5173.11 | 578 / 578 | 100% | 523.28 | 1155 / 1155 |
ovary | 100% | 4023.42 | 180 / 180 | 100% | 664.09 | 430 / 430 |
pancreas | 100% | 2959.35 | 328 / 328 | 100% | 530.20 | 178 / 178 |
stomach | 100% | 3970.67 | 359 / 359 | 100% | 439.04 | 286 / 286 |
uterus | 100% | 5090.45 | 170 / 170 | 100% | 567.10 | 459 / 459 |
skin | 100% | 5142.08 | 1808 / 1809 | 100% | 631.66 | 472 / 472 |
breast | 100% | 5123.34 | 459 / 459 | 100% | 624.42 | 1117 / 1118 |
brain | 100% | 3226.46 | 2638 / 2642 | 100% | 570.25 | 705 / 705 |
thymus | 100% | 5892.44 | 653 / 653 | 100% | 612.21 | 604 / 605 |
intestine | 100% | 4036.49 | 966 / 966 | 100% | 476.72 | 526 / 527 |
prostate | 100% | 3794.82 | 245 / 245 | 100% | 516.97 | 501 / 502 |
kidney | 100% | 5501.60 | 89 / 89 | 100% | 425.55 | 899 / 901 |
bladder | 100% | 4186.52 | 21 / 21 | 100% | 486.78 | 502 / 504 |
adrenal gland | 100% | 6064.38 | 258 / 258 | 100% | 497.63 | 229 / 230 |
liver | 100% | 3070.97 | 225 / 226 | 100% | 456.72 | 406 / 406 |
adipose | 100% | 5217.82 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 566.22 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 528.72 | 29 / 29 |
spleen | 100% | 4448.52 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 479.98 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 137.99 | 1 / 1 |
blood vessel | 100% | 5410.65 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 3560.81 | 854 / 861 | 0% | 0 | 0 / 0 |
muscle | 99% | 2468.86 | 796 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 4277.40 | 915 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006915 | Biological process | apoptotic process |
GO_0001824 | Biological process | blastocyst development |
GO_0018279 | Biological process | protein N-linked glycosylation via asparagine |
GO_0006487 | Biological process | protein N-linked glycosylation |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0031647 | Biological process | regulation of protein stability |
GO_0006486 | Biological process | protein glycosylation |
GO_0008250 | Cellular component | oligosaccharyltransferase complex |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0008047 | Molecular function | enzyme activator activity |
Gene name | DAD1 |
Protein name | Defender against cell death 1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 (Oligosaccharyl transferase subunit DAD1) (Defender against cell death 1) (DAD-1) Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 (Oligosaccharyl transferase subunit DAD1) |
Synonyms | |
Description | FUNCTION: Subunit of the oligosaccharyl transferase (OST) complex that catalyzes the initial transfer of a defined glycan (Glc(3)Man(9)GlcNAc(2) in eukaryotes) from the lipid carrier dolichol-pyrophosphate to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains, the first step in protein N-glycosylation . N-glycosylation occurs cotranslationally and the complex associates with the Sec61 complex at the channel-forming translocon complex that mediates protein translocation across the endoplasmic reticulum (ER). All subunits are required for a maximal enzyme activity (By similarity). Required for the assembly of both SST3A- and SS3B-containing OST complexes. Loss of the DAD1 protein triggers apoptosis . . FUNCTION: Subunit of the oligosaccharyl transferase (OST) complex that catalyzes the initial transfer of a defined glycan (Glc(3)Man(9)GlcNAc(2) in eukaryotes) from the lipid carrier dolichol-pyrophosphate to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains, the first step in protein N-glycosylation. N-glycosylation occurs cotranslationally and the complex associates with the Sec61 complex at the channel-forming translocon complex that mediates protein translocation across the endoplasmic reticulum (ER). All subunits are required for a maximal enzyme activity. . FUNCTION: Subunit of the oligosaccharyl transferase (OST) complex that catalyzes the initial transfer of a defined glycan (Glc(3)Man(9)GlcNAc(2) in eukaryotes) from the lipid carrier dolichol-pyrophosphate to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains, the first step in protein N-glycosylation. N-glycosylation occurs cotranslationally and the complex associates with the Sec61 complex at the channel-forming translocon complex that mediates protein translocation across the endoplasmic reticulum (ER). All subunits are required for a maximal enzyme activity. . |
Accessions | ENST00000538631.1 ENST00000543337.1 F5H895 F5GXX5 ENST00000535847.1 P61803 A0A0B4J239 ENST00000250498.9 |